BAY-3375968
- Generic Name
- BAY-3375968
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 354
- Registration Number
- NCT05537740
- Locations
- 🇧🇪
Ghent University Hospital | Drug Research Unit Department, Gent, Belgium
🇫🇷Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale, Saint Herblain, France
🇫🇷Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP), Villejuif Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath